211 related articles for article (PubMed ID: 33322348)
1. Alexander Disease Modeling in Zebrafish: An In Vivo System Suitable to Perform Drug Screening.
Candiani S; Carestiato S; Mack AF; Bani D; Bozzo M; Obino V; Ori M; Rosamilia F; De Sarlo M; Pestarino M; Ceccherini I; Bachetti T
Genes (Basel); 2020 Dec; 11(12):. PubMed ID: 33322348
[TBL] [Abstract][Full Text] [Related]
2. Aggregation-prone GFAP mutation in Alexander disease validated using a zebrafish model.
Lee SH; Nam TS; Kim KH; Kim JH; Yoon W; Heo SH; Kim MJ; Shin BA; Perng MD; Choy HE; Jo J; Kim MK; Choi SY
BMC Neurol; 2017 Sep; 17(1):175. PubMed ID: 28882119
[TBL] [Abstract][Full Text] [Related]
3. Oligomers of mutant glial fibrillary acidic protein (GFAP) Inhibit the proteasome system in alexander disease astrocytes, and the small heat shock protein alphaB-crystallin reverses the inhibition.
Tang G; Perng MD; Wilk S; Quinlan R; Goldman JE
J Biol Chem; 2010 Apr; 285(14):10527-37. PubMed ID: 20110364
[TBL] [Abstract][Full Text] [Related]
4. Suppression of GFAP toxicity by alphaB-crystallin in mouse models of Alexander disease.
Hagemann TL; Boelens WC; Wawrousek EF; Messing A
Hum Mol Genet; 2009 Apr; 18(7):1190-9. PubMed ID: 19129171
[TBL] [Abstract][Full Text] [Related]
5. The Alexander disease-causing glial fibrillary acidic protein mutant, R416W, accumulates into Rosenthal fibers by a pathway that involves filament aggregation and the association of alpha B-crystallin and HSP27.
Der Perng M; Su M; Wen SF; Li R; Gibbon T; Prescott AR; Brenner M; Quinlan RA
Am J Hum Genet; 2006 Aug; 79(2):197-213. PubMed ID: 16826512
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effects of curcumin on GFAP filament organization and down-regulation of GFAP expression in an in vitro model of Alexander disease.
Bachetti T; Di Zanni E; Balbi P; Ravazzolo R; Sechi G; Ceccherini I
Exp Cell Res; 2012 Sep; 318(15):1844-54. PubMed ID: 22705585
[TBL] [Abstract][Full Text] [Related]
7. In vitro treatments with ceftriaxone promote elimination of mutant glial fibrillary acidic protein and transcription down-regulation.
Bachetti T; Di Zanni E; Balbi P; Bocca P; Prigione I; Deiana GA; Rezzani A; Ceccherini I; Sechi G
Exp Cell Res; 2010 Aug; 316(13):2152-65. PubMed ID: 20471977
[TBL] [Abstract][Full Text] [Related]
8. Plectin regulates the organization of glial fibrillary acidic protein in Alexander disease.
Tian R; Gregor M; Wiche G; Goldman JE
Am J Pathol; 2006 Mar; 168(3):888-97. PubMed ID: 16507904
[TBL] [Abstract][Full Text] [Related]
9. Alexander disease-associated glial fibrillary acidic protein mutations in mice induce Rosenthal fiber formation and a white matter stress response.
Hagemann TL; Connor JX; Messing A
J Neurosci; 2006 Oct; 26(43):11162-73. PubMed ID: 17065456
[TBL] [Abstract][Full Text] [Related]
10. Synemin is expressed in reactive astrocytes and Rosenthal fibers in Alexander disease.
Pekny T; Faiz M; Wilhelmsson U; Curtis MA; Matej R; Skalli O; Pekny M
APMIS; 2014 Jan; 122(1):76-80. PubMed ID: 23594359
[TBL] [Abstract][Full Text] [Related]
11. The origin of Rosenthal fibers and their contributions to astrocyte pathology in Alexander disease.
Sosunov AA; McKhann GM; Goldman JE
Acta Neuropathol Commun; 2017 Mar; 5(1):27. PubMed ID: 28359321
[TBL] [Abstract][Full Text] [Related]
12. Alexander-disease mutation of GFAP causes filament disorganization and decreased solubility of GFAP.
Hsiao VC; Tian R; Long H; Der Perng M; Brenner M; Quinlan RA; Goldman JE
J Cell Sci; 2005 May; 118(Pt 9):2057-65. PubMed ID: 15840648
[TBL] [Abstract][Full Text] [Related]
13. Screening for GFAP rearrangements in a cohort of Alexander disease and undetermined leukoencephalopathy patients.
Ferreira MC; Dorboz I; Rodriguez D; Boespflug Tanguy O
Eur J Med Genet; 2015 Sep; 58(9):466-70. PubMed ID: 26208460
[TBL] [Abstract][Full Text] [Related]
14. Clinical aspects and pathology of Alexander disease, and morphological and functional alteration of astrocytes induced by GFAP mutation.
Yoshida T; Nakagawa M
Neuropathology; 2012 Aug; 32(4):440-6. PubMed ID: 22118268
[TBL] [Abstract][Full Text] [Related]
15. Glial fibrillary acidic protein exhibits altered turnover kinetics in a mouse model of Alexander disease.
Moody LR; Barrett-Wilt GA; Sussman MR; Messing A
J Biol Chem; 2017 Apr; 292(14):5814-5824. PubMed ID: 28223355
[TBL] [Abstract][Full Text] [Related]
16. Mild functional effects of a novel GFAP mutant allele identified in a familial case of adult-onset Alexander disease.
Bachetti T; Caroli F; Bocca P; Prigione I; Balbi P; Biancheri R; Filocamo M; Mariotti C; Pareyson D; Ravazzolo R; Ceccherini I
Eur J Hum Genet; 2008 Apr; 16(4):462-70. PubMed ID: 18197187
[TBL] [Abstract][Full Text] [Related]
17. A case of severe Alexander disease with de novo c. 239 T > C, p.(F80S), in GFAP.
Matsumoto A; Tulyeu J; Furukawa R; Watanabe C; Monden Y; Nozaki Y; Mori M; Namekawa M; Jimbo EF; Aihara T; Yamagata T; Osaka H
Brain Dev; 2018 Aug; 40(7):587-591. PubMed ID: 29573842
[TBL] [Abstract][Full Text] [Related]
18. Relative stabilities of wild-type and mutant glial fibrillary acidic protein in patients with Alexander disease.
Heaven MR; Wilson L; Barnes S; Brenner M
J Biol Chem; 2019 Oct; 294(43):15604-15612. PubMed ID: 31484723
[TBL] [Abstract][Full Text] [Related]
19. Dynamics of mutated GFAP aggregates revealed by real-time imaging of an astrocyte model of Alexander disease.
Mignot C; Delarasse C; Escaich S; Della Gaspera B; Noé E; Colucci-Guyon E; Babinet C; Pekny M; Vicart P; Boespflug-Tanguy O; Dautigny A; Rodriguez D; Pham-Dinh D
Exp Cell Res; 2007 Aug; 313(13):2766-79. PubMed ID: 17604020
[TBL] [Abstract][Full Text] [Related]
20. Antisense suppression of glial fibrillary acidic protein as a treatment for Alexander disease.
Hagemann TL; Powers B; Mazur C; Kim A; Wheeler S; Hung G; Swayze E; Messing A
Ann Neurol; 2018 Jan; 83(1):27-39. PubMed ID: 29226998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
